JP6720208B2 - Ｃ４．４ａを検出するための抗体、組成物、及び免疫組織化学法 - Google Patents

Ｃ４．４ａを検出するための抗体、組成物、及び免疫組織化学法 Download PDF

Info

Publication number
JP6720208B2
JP6720208B2 JP2017554283A JP2017554283A JP6720208B2 JP 6720208 B2 JP6720208 B2 JP 6720208B2 JP 2017554283 A JP2017554283 A JP 2017554283A JP 2017554283 A JP2017554283 A JP 2017554283A JP 6720208 B2 JP6720208 B2 JP 6720208B2
Authority
JP
Japan
Prior art keywords
seq
amino acids
antibody
sequence
monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017554283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515071A5 (enExample
JP2018515071A (ja
Inventor
フェルナンド ホセ レベロ ド コウト，
フェルナンド ホセ レベロ ド コウト，
チミン リャオ，
チミン リャオ，
イーフェイ チュー，
イーフェイ チュー，
Original Assignee
スプリング バイオサイエンス コーポレーション
スプリング バイオサイエンス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スプリング バイオサイエンス コーポレーション, スプリング バイオサイエンス コーポレーション filed Critical スプリング バイオサイエンス コーポレーション
Publication of JP2018515071A publication Critical patent/JP2018515071A/ja
Publication of JP2018515071A5 publication Critical patent/JP2018515071A5/ja
Application granted granted Critical
Publication of JP6720208B2 publication Critical patent/JP6720208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017554283A 2015-04-17 2016-04-13 Ｃ４．４ａを検出するための抗体、組成物、及び免疫組織化学法 Active JP6720208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149239P 2015-04-17 2015-04-17
US62/149,239 2015-04-17
PCT/EP2016/058135 WO2016166169A1 (en) 2015-04-17 2016-04-13 Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a

Publications (3)

Publication Number Publication Date
JP2018515071A JP2018515071A (ja) 2018-06-14
JP2018515071A5 JP2018515071A5 (enExample) 2019-03-07
JP6720208B2 true JP6720208B2 (ja) 2020-07-08

Family

ID=55702016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554283A Active JP6720208B2 (ja) 2015-04-17 2016-04-13 Ｃ４．４ａを検出するための抗体、組成物、及び免疫組織化学法

Country Status (6)

Country Link
US (2) US10948493B2 (enExample)
EP (1) EP3283522A1 (enExample)
JP (1) JP6720208B2 (enExample)
AU (1) AU2016249839B2 (enExample)
CA (1) CA2982536C (enExample)
WO (1) WO2016166169A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
WO2022261403A1 (en) * 2021-06-11 2022-12-15 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting upar and uses thereof
AU2023234686A1 (en) * 2022-03-16 2024-08-29 Pentixapharm Ag Antibodies against lypd3
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN116086919B (zh) * 2023-02-20 2024-01-26 深圳裕策生物科技有限公司 一种肺癌和/或胰腺癌样本的染色方法及试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023553A2 (en) 1999-09-29 2001-04-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
ATE556845T1 (de) 2001-07-20 2012-05-15 Life Technologies Corp Lumineszierende nanopartikel und ihre herstellung
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
US7632652B2 (en) 2003-06-24 2009-12-15 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
DK2078197T3 (en) 2006-11-01 2016-05-23 Ventana Med Syst Inc Haptenes, hapten conjugates, compositions thereof and processes for their preparation and use
MX343879B (es) * 2007-05-21 2016-11-25 Alderbio Holdings Llc Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
ES2667729T3 (es) * 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
JP5989544B2 (ja) * 2009-12-09 2016-09-07 バイエル・ファルマ・アクティエンゲゼルシャフト 抗Ｃ４．４ａ抗体およびその使用
JP5881604B2 (ja) 2010-06-15 2016-03-09 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
TWI582112B (zh) * 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）
CN103688176A (zh) * 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
WO2012158780A2 (en) 2011-05-16 2012-11-22 The Regents Of The University Of Michigan Lung cancer signature
KR20150013935A (ko) 2012-06-08 2015-02-05 갓코 호진 긴키 다이가쿠 트랜스포터에 대한 항체 및 이의 용도
WO2014183119A1 (en) 2013-05-10 2014-11-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging probes for lung cancer inoperative guidance
US20160115237A1 (en) * 2013-05-24 2016-04-28 The University Of British Columbia Cell senescence markers as diagnostic and therapeutic targets
AU2015315332A1 (en) * 2014-09-09 2017-03-30 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
WO2016166169A1 (en) * 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a

Also Published As

Publication number Publication date
WO2016166169A1 (en) 2016-10-20
US11719699B2 (en) 2023-08-08
US20180031566A1 (en) 2018-02-01
EP3283522A1 (en) 2018-02-21
CA2982536A1 (en) 2016-10-20
US20210164985A1 (en) 2021-06-03
US10948493B2 (en) 2021-03-16
AU2016249839A1 (en) 2017-09-21
JP2018515071A (ja) 2018-06-14
AU2016249839B2 (en) 2021-09-09
CA2982536C (en) 2023-04-18

Similar Documents

Publication Publication Date Title
JP6720208B2 (ja) Ｃ４．４ａを検出するための抗体、組成物、及び免疫組織化学法
Abildgaard et al. Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits
JP6324970B2 (ja) 抗ウロプラキンｉｉ抗体システムおよび方法
CN103293307B (zh) Satb2蛋白作为结肠直肠癌标记的应用
JP6445467B2 (ja) 抗ｐ４０抗体システムおよび方法
Nasr et al. Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases
JP2016500659A5 (enExample)
US10718773B2 (en) Immunohistochemistry scoring methods and compositions
CN108700586B (zh) 用于评估癌症发生的风险的组合物和方法
JP2020160076A (ja) 免疫チェックポイント阻害剤の奏効性の判定を補助する方法、試薬キット、装置及びコンピュータプログラム
Nishimura et al. HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens
EP3677910B1 (en) Diagnosing pancreatic cancer using methionyl-trna synthetase and ck19
Katabi Oncocytoid salivary tumors: Differential diagnosis and utility of newly described immunohistochemistry
US20240393338A1 (en) Tibtech compositions and methods for detecting cdh17
Dai et al. Analysis of the clinical significance of DCLK1+ colorectal cancer using novel monoclonal antibodies against DCLK1
WO2018208122A1 (ko) 담도 세포에서 메티오닐-타알엔에이 합성효소를 이용한 담도암 진단 방법
US20210238305A1 (en) Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof
Shi et al. An update on immunohistochemistry in translational cancer research
Moonen et al. Development and verification of new monoclonal orthopedia homeobox (OTP) specific antibodies for pulmonary carcinoid diagnostics
Kim et al. Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study
Niinimäki et al. Absence of orthopaedia homeobox protein (OTP) expression is associated with disease spread and adverse outcome in pulmonary carcinoid tumour patients
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
Santra et al. Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
JP2024042026A (ja) 治療薬による処置から利益を受けうる被験体を特定するためのサンドウィッチｅｌｉｓａ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200617

R150 Certificate of patent or registration of utility model

Ref document number: 6720208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250